Medical Technologies

ARPA-H Funds Projects to Develop Biosensors with More Than $100 Million

ARPA-H has awarded more than $100 million to four entities developing wearable devices to monitor indicators of heart failure, inflammation, and perimenopausal transitions. The program relies on designs that can integrate multiple sensors, with testing stages including in-body prototypes and clinical trials.

2026-10-05
3 min read
255 views
certi.news Editorial Team
ARPA-H Funds Projects to Develop Biosensors with More Than $100 Million

The Advanced Research Projects Agency for Health (ARPA-H) announced more than $100 million in awards to four entities working to develop wearable biosensors for monitoring indicators associated with heart failure, heart attacks, inflammation, and perimenopausal transitions. The agency plans a total commitment of $117.4 million over 4.5 years under the Delphi program.

Four Paths for Developing the Sensors

The Massachusetts Institute of Technology (MIT) received the largest award, worth up to $37.9 million, to develop a clinical-grade wearable patch that continuously monitors indicators of heart failure. According to ARPA-H, the patch will draw its energy from the patient’s body heat and will use on-chip artificial intelligence designed for low power consumption.

Novelna, a California-based proteomics company, will receive up to $33.2 million to develop a patch that measures inflammation after a heart attack, with the aim of helping reduce hospital readmissions. The device will use the human body to transmit data, helping extend battery life.

New York University received up to $30.8 million to develop a patch that continuously monitors inflammation through microscopic probes placed under the skin. The design includes DNA-based sensors, along with energy harvesting from radio-frequency sources such as Bluetooth and Wi-Fi.

The University of Washington received up to $7.5 million to develop an ultra-low-power patch that tracks changes associated with perimenopause. The team will use proteins to measure biomarkers in sweat, with the possibility of regenerating and reusing these proteins by modifying the local pH of the sensor, maintaining its sensitivity and reliability for longer periods.

What Does the Delphi Program Change?

ARPA-H launched the program in March with the aim of overcoming the limitations of wearable sensing platforms typically designed for a single application. The program’s vision is based on a “chiplet” approach that allows developers to integrate different biosensors and switch them according to the indicators to be measured, rather than building a separate platform for each use.

The practical importance of this approach is not limited to funding, but also involves an attempt to address persistent challenges in wearable medical devices: long-term operation, power consumption, data transmission, and expanding the range of measurable indicators. However, the source describes projects still under development and does not yet establish that any of the devices are ready for clinical or commercial use.

Validation Stages and Limitations

ARPA-H expects the teams to demonstrate full interoperability and comply with secure communication standards during the first 18 months. After 24 months, they are expected to provide in-body prototypes and identify additional sensors to expand the range of biomarkers. By month 54, the agency aims to complete clinical trials or human-factors studies.

These timelines mean that the projects’ medical value will remain tied to the results of subsequent testing, including measurement accuracy, sensor stability, and the safety of their use in humans. The announced awards are also potential maximum amounts, not necessarily funding paid entirely in advance.

News source
c
Author

certi.news Editorial Team

What you need to know

ARPA-H has allocated more than $100 million to four organizations to develop wearable patches and biosensors for monitoring indicators of heart failure, inflammation, and perimenopausal changes. The projects are still under development and will require in-body prototypes and clinical trials before their medical or commercial readiness can be established.

  • ARPA-H plans a total commitment of $117.4 million over 4.5 years through the Delphi program.
  • The Massachusetts Institute of Technology received a grant of up to $37.9 million to develop a patch that monitors indicators of heart failure and draws power from body heat.
  • Novelna will develop a patch to measure inflammation after heart attacks, while New York University will develop a patch that uses microscopic sensors beneath the skin.
  • The University of Washington is working on a low-power patch to track indicators associated with perimenopause through proteins in sweat.
  • The Delphi program uses a chiplet approach to integrate multiple biosensors and switch them according to the indicators being measured.
  • The agency is targeting in-body prototypes after 24 months and clinical trials or human-factors studies by month 54.

FAQ

How much is the total funding for the Delphi program?

ARPA-H plans a total commitment of $117.4 million over 4.5 years, with maximum grants to four organizations totaling more than $100 million.

Are the devices ready for clinical or commercial use?

No. The article states that the projects are still under development and that their readiness will depend on the results of testing, in-body prototypes, and subsequent clinical trials.

What is the purpose of the chiplet approach?

The approach is intended to integrate different biosensors and switch among them according to the indicators being measured, rather than creating a separate platform for each use case.

Which health indicators are the projects targeting?

They include indicators associated with heart failure, heart attacks and inflammation, and perimenopausal changes.

In the same category

You may also like

View all news